[{"id":"26912b3a-874b-41d0-8280-5bf68e728ed7","acronym":"IOV-CLL-01","url":"https://clinicaltrials.gov/study/NCT04155710","created_at":"2021-01-18T20:16:34.491Z","updated_at":"2024-07-02T16:35:04.463Z","phase":"Phase 1/2","brief_title":"Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL","source_id_and_acronym":"NCT04155710 - IOV-CLL-01","lead_sponsor":"Iovance Biotherapeutics, Inc.","biomarkers":" TP53 • IL2","pipe":" | ","alterations":" TP53 mutation • TP53 mutation + Chr del(17p)","tags":["TP53 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 mutation + Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IOV-2001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/19/2020","start_date":" 02/19/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-10"}]